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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
Our main objective is to assess the effectiveness of follow-up services for ICU survivors that aim to identify and address unmet health
needs related to the ICU period. We aim to assess the effectiveness in relation to health-related quality of life, mortality, depression and
anxiety, post-traumatic stress disorder, physical function, cognitive function, ability to return to work or education and adverse events.
Our secondary objectives are, in general, to examine both the various ways that follow-up services are provided and anymajor influencing
factors. Specifically, we aim to explore: the effectiveness of service organisation (physician versus nurse led, face to face versus remote,
timing of follow-up service); possible differences in services related to country (developed versus developing country); and whether
participants had delirium within the ICU setting.
B A C K G R O U N D
In 2014 to 2015, approximately 150,000 patients were admitted
to adult intensive care units (ICUs) in the UK - a large percentage
of whom survived (ICNARC 2016). An ever-increasing number
of people, in the UK and globally, are surviving the ICU, and
short-term mortality for critical illnesses is decreasing in general
(Needham 2012). Despite this progress, ICU stay has been linked
with a number of physical and psychological sequelae which af-
flict these survivors - potentially for years after critical illness. ICU
follow-up services are relatively recent developments in healthcare
systems, the purposes of which are to help address this wide vari-
ety of impairments by identifying and addressing patients’ health
needs directly or by providing access to additional healthcare ser-
vices.
Description of the condition
Critical illness, and the ICU stay itself, can be traumatic experi-
ences which have been known to cause physical and psychological
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distress that can extend far beyond the initial illness and any short-
term treatment. The long-term problems arising from the ICU,
known as ’post-intensive care syndrome’ (PICS) (Needham 2012),
include mortality, post-traumatic stress disorder (PTSD), anxiety,
depression and physical impairments, and can also include sexual
dysfunction, amnesia of the ICU period, and various related so-
cial problems (Griffiths 2007; Oeyen 2010). PICS not only affects
ICU survivors, but also amplifies the burden for their families and
dramatically increases costs for healthcare systems (Jones 1998;
Needham 2011).
Mortality figures at one year after discharge range from 26% to
63%, and those for five years after discharge are reported to be
between 40% and 58% (Williams 2005). Additionally, between
19% to 22%of ICU survivors are affected by PTSDup to ten years
after critical illness, and for survivors of acute respiratory distress
syndrome (ARDS) this figure could be as high as 44% (Davydow
2008a; Davydow 2008c).
Anxiety may affect 23% to 48% of ARDS survivors up to 28
months after illness. The incidence of depression in the same
group ranges from 17% to 43%, and this incidence may affect 8%
to 57% of the general ICU population at 14 months (Davydow
2008b; Davydow 2008c). The quality of life (QoL) scores of ICU
survivors are lower than average (for an age- and gender-matched
population), and while research shows that QoL and basic func-
tionality does begin to slowly improve, this disparity compared
with the general population tends to remain for at least five years
after discharge (Cuthbertson 2005; Cuthbertson 2010; Eddleston
2000; Oeyen 2010), and may never fully return to preadmittance
levels (van der Schaaf 2009). An individual’s QoL can be further
affected by sexual dysfunction, or by an inability to return to work
(Griffiths 2006; Myhren 2010; Williams 2011). Even with this
research, there exist significant gaps in our knowledge of post-
ICU cognitive morbidities, and more attention may need to be
paid in particular to the impact of delirium (Cuthbertson 2009;
Needham 2012; NICE 2009; Pandharipande 2013).
Description of the intervention
For this review we define an ICU follow-up strategy as any ser-
vice set up to address specifically the various health needs of ICU
survivors, to prevent the development of physical, psychological
and social problems over the long term. There is, however, no one
acceptedmodel for such services (Rattray 2007). TheUKhas been
at the centre of research into critical care follow up (Lasiter 2016;
Williams 2008), and there has been substantial investment in ICU
follow-up services, leading to a doubling of their number between
2002 and 2006 (Cuthbertson 2003; Griffiths 2006).Though the
first follow-up clinic in the UK was set up in 1985 (Griffiths
2006), and following official recommendations coming from the
King’s Fund Panel in 1989 (King’s Fund 1989) and the ‘Critical
to Success’ audit commission in 1999 (Audit Commission 1999),
the development of ICU clinics has been an ad hoc, experimental
process, not a systematic one (Angus 2003; Jensen 2015). Today,
still, there is no standardisation of such services across National
Health Service (NHS) trusts or other healthcare systems globally.
Indeed, on a global level ICU follow-up programmes have seen
mixed levels of attention and implementation. A recent ’push’
by the Institute of Medicine in the USA has resulted in greater
attention being paid to this important aspect of post-critical care
(Lasiter 2016), with systems such as the Indiana University School
of Medicine’s Critical Care Recovery Center (CCRC) being set up
(Khan 2015). In Scandinavian countries (Norway, Denmark and
Sweden) there is evidence of local initiatives dating back to the early
1990s. While UK services have emphasised physical rehabilitation
(NICE 2009) the programmes in the Scandinavian countries have
tended to focus on patient-led initiatives, including diaries and
dialogue (Egerod 2013; Jensen 2015). There appears to be a lack
of available data fromother countries, which is perhaps no surprise
given the slow implementation even in more developed healthcare
systems.
Types of services that may be offered to ICU survivors range from
informal interviews to more organised sessions. They may be pa-
tient led and focus around the sharing of experiences, or led by
healthcare personnel with the purpose of providing information
to the patient; equally, they may be focused around physical re-
habilitation, or around addressing cognitive dysfunction (NICE
2009). Guidelines published by the National Institude for Health
and Care Excellence (NICE) recommended both that preventa-
tive measures should be started in the ICU setting and that mul-
tidisciplinary functional assessments should be conducted by ap-
propriately trained personnel two to three months after ICU dis-
charge (NICE 2009). Importantly however, these guidelines ac-
knowledge the limitations of the current consensus surrounding
ICU follow up (NICE 2009).
How the intervention might work
The general aims of a follow-up service in this review are to: pro-
vide a forum in which to identify and address any unmet health
needs; and to identify possible PICS, and allow for their further
management within or without the hospital setting. How such a
service might achieve these aims can vary widely, however. Follow-
up services may take the form of informal meetings that facilitate
a patient-led sharing of experiences which can provide reassurance
to the ICU survivor and potentially reduce depression or anxiety;
or they may involve access to standard general practitioner ser-
vices.
More organised sessions, which may either be nurse or physician
led, might involve discussion of specific physical or psychological
conditions and subsequent referral to appropriate health providers
to manage these conditions. A follow-up service might be con-
ducted face to face or by remote access. It might be assessed using
locally-derived questionnaires, or through standardised question-
naires using validated scales. For complex interventions such as
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this one, a preferred model may be one that is tailored to local
circumstances rather than being completely standardised (Craig
2008). Equally, the inherent heterogeneity of the patient popu-
lation within any single ICU might further complicate any stan-
dardisation of follow-up services. It has been suggested, for exam-
ple, that patients who have had a longer ICU stay, or who have had
incidents of delirium, may react to follow-up services differently.
So while it might be beneficial for clinics to target their resources
at those most likely to benefit (Aitken 2015; Cuthbertson 2009;
Jensen 2015), the lack of a thorough epidemiological study base
for these differences makes conclusions in this area speculative
(Needham 2012).
Globally, ICUs treat people with a large range of diseases and
general afflictions, and varying severities of conditions, patient
backgrounds and socioeconomic factors. It is feasible that follow-
up services may be more beneficial to particular patient groups.
For example, the socioeconomic conditions of an individual can
affect quality of life, cause or exacerbate anxiety and depression,
and affect physical function, and, in less economically-developed
countries, mortality. Another important consideration, and one
which has been overlooked in much of the literature (Williams
2008), is that of ICU access. Access to hospital-based follow-up
services, which may be relatively simple for UK-based patients,
has the potential to be extremely difficult for those living in very
large tertiary care catchment areas. This means that conclusions
reached about these services may not be relevant for clinicians and
patients in rural areas around the world.
Why it is important to do this review
Though there is a growing civil, scholarly, and governmental de-
sire for information on the role that ICU follow-up services might
play within an integrated recovery process which starts in the ICU
and continues long afterwards, there has been, and still is, a lack
of medical consensus (Angus 2003; NICE 2009). In the UK, the
USA and around the world, ICU follow-up initiatives have not re-
ceived as much dedicated funding or widespread implementation
as those of oncology care, spinal injury care, or military veterans’
care (Needham 2012). ICU follow-up services appear intuitively
beneficial (Cuthbertson 2003; Rattray 2007), but it is still impor-
tant that they are grounded in the principles of evidence-based
medicine.
To date, there has been no Cochrane review of the efficacy of ICU
follow-up services as a general system of care. We have identi-
fied a number of reviews dedicated to this subject (Jensen 2015;
Niven 2014; Williams 2008). These reviews, among other differ-
ences, either require updating (Williams 2008), or have different
emphases (Jensen 2015; Niven 2014). Niven 2014, for example,
focuses on ICU transition services and the risk of readmission,
whereas Jensen 2015 has subtle differences regarding inclusion cri-
teria for studies. Jensen and colleagues only included randomised
trials. Our emphasis in this review will be on both randomised and
non-randomised trials and will be directed towards services that
are both delivered by a healthcare professional and address unmet
health needs related to the ICU period. This is an area of clinical
importance which warrants a systematic approach.
O B J E C T I V E S
Our main objective is to assess the effectiveness of follow-up ser-
vices for ICU survivors that aim to identify and address unmet
health needs related to the ICU period. We aim to assess the effec-
tiveness in relation to health-related quality of life, mortality, de-
pression and anxiety, post-traumatic stress disorder, physical func-
tion, cognitive function, ability to return to work or education
and adverse events.
Our secondary objectives are, in general, to examine both the
various ways that follow-up services are provided and any major
influencing factors. Specifically, we aim to explore: the effectiveness
of service organisation (physician versus nurse led, face to face
versus remote, timing of follow-up service); possible differences in
services related to country (developed versus developing country);
and whether participants had delirium within the ICU setting.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised trials and non-randomised trials. We
will also include interrupted time series studies and controlled be-
fore-after studies. Controlled before-after studies can be defined as
those in which observations are made before and after the imple-
mentation of an intervention, while interrupted time series studies
use observations at multiple time points before and after an in-
tervention (the interruption) in order to detect significant change
over time (EPOC 2016). It has been acknowledged that while true
experimental designs are preferred, they are not always practicable
in trials with multi-faceted interventions (Craig 2008), and may
not be the most appropriate study design for examining a system
of care, rather than a single intervention (Cuthbertson 2003). We
will include full-text studies, conference abstracts and unpublished
data identified through initial database searches which contain
sufficient information on study type, intervention data, and out-
comes.We will not exclude studies based on outcomes or methods
of analysis, but we will exclude interrupted time series designs for
which a necessary reanalysis of data is not possible (see Measures
of treatment effect). We will also exclude interrupted time series
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studies if they do not have a clearly defined time point for the
intervention and at least three data points before and after the
intervention (EPOC 2016).
Types of participants
We will include adults who have been discharged from hospital
following a stay in an ICU that required level three care. We will
not exclude participants based on the reason theywere admitted to
the ICU, so long as they were subject to level three care.We define
level three care, or the equivalent grade in other healthcare systems,
as requiring advanced respiratory support, or care which requires
the artificial support of at least two organs (Intensive Care Society
2009). We will include participants that have been admitted to
any ICU, to include admission to high-dependency or critical
care units or other hospital wards specifically designed to cater for
patients who are critically ill.
We will exclude participants who are in any existing rehabilitation
programme, for example those associated with traumatic brain in-
jury, spinal cord injury, military trauma and cancer or cardiac care.
We will not exclude otherwise eligible patients based on location,
geographical dispersion, sex, or any other factor.
Types of interventions
We will include studies that assess a follow-up service (interven-
tion), attendedby ICU survivors on at least one occasion compared
to either no follow-up service or standard care (control). We de-
fine a follow-up service as a consultation delivered by a healthcare
professional or appropriately trained other person, which seeks to
specifically identify or address unmet health needs directly related
to the ICU period. We will include studies in which the service
is conducted either face to face or remotely, for example through
email or telephone contact, and which occurs at any time within
six months of discharge from hospital. We will include studies in
which the follow-up service seeks to address needs through im-
mediate support or subsequent referrals. We will exclude stud-
ies that offer a follow-up service that only provides general (non-
ICU related) information or educational materials to the patient,
and we will exclude studies that are not delivered by a healthcare
professional or appropriately trained other person. Standard care
(control group) may include general practitioner visits and care
related to ongoing known medical conditions that are not targeted
at identifying and addressing unmet needs related to the period
spent in ICU.
Types of outcome measures
We will assess the effectiveness of follow-up services by measuring
differences in physical and psychological outcomes for study par-
ticipants. Our main outcome is an overall assessment of health-
related quality of life (HRQoL). We will collect data from studies
that have used a validated tool to assess HRQoL and report an
overall mean value for study participants from the validated tools,
such as the SF-36 and Euroqol EQ-5D scales. The SF-36 scale
assesses the following: physical functioning, social functioning,
role limitations, pain, mental health, vitality, and general health
perceptions; while the EQ-5D scale assesses mobility, self care,
main activity, family/leisure activity, pain/discomfort, anxiety and
depression (Brazier 1993; RAND). We will report physical func-
tion, for which data may have been collected from components
of scales such as the SF-36 and EQ-5D, or results of tests such as
the six-minute walk test. Cognitive function data will be collected
according to any validated scale used by the study authors. We will
report psychological outcomes in terms of anxiety or depression or
both, and, again, may collect these data from components of the
above scales or other validated tools such as HADS-A and HADS-
D (Zigmond 1983). We will collect data on the number of deaths
from any cause up to 12 months post-ICU. For post-traumatic
stress disorder (PTSD) we will, again, measure data from validated
scales such as PDS (Jones 2010; McCarthy 2008) or DSM-III, IV
or V (American Psychiatric Association 2013; U.S. Department
of Veterans Affairs). Data for the ability of participants to return
to work may be collected in the percentage of patients who have
returned to work at the follow-up time point.
We will collect data for adverse events as reported by study au-
thors. Examples of adverse events may include increased or con-
tinued dependency on medical services rather than a transition
into activities of daily living; potential exacerbation of PICS, for
example because of formalised recollection of ICU experiences; or
duplication or fragmentation of medical services as noted by study
investigators, for example because the patient is offered access to
an ICU physician-led follow-up service alongside other rehabilita-
tion services. It is unlikely that these events will be reported using
validated scales and we will report these events in the narrative of
the review.
We will collect data for all outcomes at time points measured by
study authors up to 12 months post-ICU discharge.
In summary, we will collect data for the following outcomes:
Primary outcomes
1. Health-related quality of life (HRQoL)
2. All cause mortality
3. Depression and anxiety
Secondary outcomes
1. Post-traumatic stress disorder (PTSD)
2. Physical function
3. Cognitive function
4. Ability to return to work or education
5. Adverse effects
Reporting of the outcomes listed here will not be an inclusion
criterion for the review and we will include studies regardless of
the assessed outcomes.
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Search methods for identification of studies
Electronic searches
The Effective Practice andOrganisation of Care (EPOC) Informa-
tion Specialist (IS) will develop the search strategies in consultation
with the review authors. We will search the Cochrane Database
of Systematic Reviews (CDSR) and the Database of Abstracts of
Reviews of Effects (DARE) for related systematic reviews.
We will search the following databases for primary studies, from
inception to the date of search.
• Cochrane Central Register of Controlled Trials
(CENTRAL) (current issue).
• MEDLINE (via Ovid) (from 1985 to the present).
• Embase (via Ovid) (from 1985 to the present).
• CINAHL (via EBSCO) (from 1985 to the present).
We will use twomethodology search filters in the database searches
to limit retrieval to appropriate study designs: a modified version
of the Cochrane Highly Sensitive Search Strategy (sensitivity- and
precision-maximizing version - 2008 revision; Lefebvre 2011) to
identify randomised trials (Higgins 2011); and an EPOCmethod-
ology filter to identify non-randomised designs. See Appendix 1
for the MEDLINE search strategy, which we will adapt for other
databases. We will not apply any limits on languages.
Searching other resources
Trial registries
We will search the following trial registers.
• WHO ICTRP (World Health Organization International
Clinical Trials Registry Platform (www.who.int/ictrp).
• US National Institutes of Health Ongoing Trials Register,
ClinicalTrials.gov (www.clinicaltrials.gov).
Grey literature
We will conduct a grey literature search to identify studies not
indexed in the databases listed above. We will search the following
sources.
• Healthcare Management Information Consortium
(HMIC).
• National Technical Information Service (NTIS).
• National Institute for Health and Clinical Excellence
(NICE).
• OpenGrey (www.opengrey.eu).
• Agency for Healthcare Research and Quality (AHRQ).
We will also review reference lists of all included studies and rele-
vant systematic reviews for additional potentially-eligible primary
studies. We will contact authors of included studies and relevant
reviews to clarify reported published information and to seek un-
published data. We will contact researchers with expertise rele-
vant to the review topic and to EPOC interventions. We will con-
duct cited reference searches for all included studies in ISI Web
of Knowledge and screen individual journals and conference pro-
ceedings (e.g. handsearch).We will report all strategies used in ap-
pendices, including a list of sources screened and relevant reviews
and primary studies reviewed.
Data collection and analysis
Selection of studies
We will download all titles and abstracts retrieved by electronic
searching to a reference management database and remove dupli-
cates. Sharon Lewis (SL) and Oliver Schofield-Robinson (OSR)
will independently screen all titles and abstracts and will remove
studies that are very unlikely to be eligible. We will identify poten-
tially-eligible randomised trials and interrupted time series studies
separately. If no abstract is available but the title is possibly relevant,
we will obtain the full text of the article. We anticipate that we
may need to get more full texts for controlled before-after and in-
terrupted time series studies as abstracts may not contain sufficient
detail to allow classification (Higgins 2011, Section 13.3.1.3). We
will resolve any disagreement through informal discussion, and we
will address any lack of consensus to a third author, Phil Alderson
(PA), who will make a final decision.
When we have screened all titles and abstracts, SL and OSR will
independently review the full text of potentially-relevant titles and
record our decision on the study eligibility section of the data ex-
traction form (EPOC 2013a). This has been modified to account
for the interventions featured in this review. A draft version of this
form is presented in Appendix 2.Wewill resolve any disagreement
through discussion or, if required, we will consult a third review
author (PA).
Studies that initially appeared to meet the inclusion criteria but
were later excluded will be listed with reasons for exclusion in the
table ’Characteristics of excluded studies’. We will collate multiple
reports of the same study so that each study rather than each
report is the unit of interest in the review. We will also provide any
information we can obtain about ongoing studies. We will record
the selection process in sufficient detail to complete a PRISMA
flow diagram (Liberati 2009).
Data extraction and management
For data extraction and management for all study designs, we will
use Covidence software (Covidence). We will create a template
using an adapted standard EPOC data collection form (EPOC
2013a) for study characteristics and outcome data (Appendix 2)
which we will pilot on at least one study in the review. Two review
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authors (SR and OSR) will independently extract the following
study characteristics from the included studies.
1. Methods: study design, number of study centres and
location (to include description of rural or urban centre), study
setting, date of study, follow-up time point.
2. Participants: number, mean age, age range, ethnicity,
gender, socioeconomic descriptions (e.g. economic status,
education and employment status), APACHE II score, presence
of ARDS, reason for ICU stay, episodes of delirium whilst in the
ICU (CAM-ICU score; Ely 2001), withdrawals, diagnostic
criteria, length of stay in the ICU, duration of sedation, inclusion
criteria, exclusion criteria, other relevant characteristics.
3. Interventions: intervention components, comparison,
direct or remote clinic, time point of intervention, time point of
follow up, physician or nurse led, number of attended clinics.
4. Outcomes: main and other outcomes specified and
collected, time points reported.
5. Notes: funding for trial, notable conflicts of interest of trial
authors, ethical approval
We will note in the ’Characteristics of included studies’ table if
outcome data were reported in an unusable way, for example in
graphs or figures with unclearly labelled axes. We will resolve dis-
agreements by consensus or by involving a third review author
(PA).
Assessment of risk of bias in included studies
Two review authors (SL and OSR) will independently assess risk
of bias for each study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011),
and guidance from the EPOC group. Any disagreement will be
resolved by discussion or by involving a third review author (PA).
For randomised trials and controlled before-after studies we will
assess the following criteria (EPOC 2009).
1. Was the allocation sequence adequately generated?
2. Was the allocation adequately concealed?
3. Were baseline outcome measurements similar?
4. Were baseline characteristics similar?
5. Were incomplete outcome data adequately addressed?
6. Was knowledge of the allocated interventions adequately
prevented during the study?
7. Was the study adequately protected against contamination?
8. Was the study free from selective outcome reporting?
9. Was the study free from other risks of bias?
For interrupted time series studies, we will assess the following
criteria (EPOC 2009).
1. Was the intervention independent of other changes?
2. Was the shape of the intervention effect prespecified?
3. Was the intervention unlikely to affect data collection?
4. Was knowledge of the allocated interventions adequately
prevented during the study?
5. Were incomplete outcome data adequately addressed?
6. Was the study free from selective outcome reporting?
7. Was the study free from other risks of bias?
We will judge each potential source of bias as high, low, or un-
clear and provide a quote from the study report together with a
justification for our judgment in the ’Risk of bias’ table. We will
summarise ’Risk of bias’ judgements across different studies for
each of the domains listed. It is not feasible to blind personnel or
participants to the study intervention in this review and therefore
we will judge all randomised trials to have a high risk of perfor-
mance bias for this review. There may be similar risks for detection
bias because this review will contain patient-assessed outcomes,
for example using validated questionnaires. We will assess blinding
of outcome assessment for each reported outcome and consider
whether lack of blinding for the each outcome would introduce a
risk of bias to the results.
Where information on risk of bias relates to unpublished data
or correspondence with a study author, we will note this in the
’Risk of bias’ table. We will not exclude studies on the grounds
of their risk of bias, but will clearly report the risk of bias when
presenting the results of the studies. We will use EPOC ’Risk of
bias’ guidance information to help judgements (EPOC 2009). A
draft of the modified ’Risk of bias’ table is given in Appendix 3.
Assesment of bias in conducting the systematic
review
We will conduct the review according to this published protocol
and report any deviations from it in the ’Differences between pro-
tocol and review’ section of the systematic review.
Measures of treatment effect
For randomised trials and controlled before-after studies, we will
collect continuous data from validated scales (HRQoL, depres-
sion and anxiety, PTSD, physical function, cognitive function),
reported as mean scores at the end of follow-up time point (6
months or 12 months). If data are recorded as dichotomous in the
included studies, we will contact the study authors for any avail-
able continuous data. We will collect dichotomous data for mor-
tality, the number of participants who are able to return to work
at the end of follow-up and the number of participants reporting
an adverse event.
For interrupted time series designs, we will report a comparison of
time trends before and after introduction of the intervention for
each of our outcomes as reported by study authors. If necessary,
we will reanalyse the data to ensure that study authors have not
used inappropriate analyses (EPOC 2013b). In the event that data
are presented graphically we will use software (Plot Digitizer) to
read values from graphs and we will use guidance from EPOC
to organise and reanalyse the data appropriately (EPOC 2013b;
EPOC 2013c). As mentioned, if, after consultation, the data are
still unsuitable for reanalysis, we will exclude the studies from our
analyses.
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Unit of analysis issues
If there is a unit of analysis error in the reported analysis for a
study and there is insufficient information to reanalyse the results,
we will contact the study authors to obtain the necessary data. If
these data are not available, we will not report confidence intervals
or P values for which there is a unit of analysis error. Because we
are including within this review not only randomised trials but
also non-randomised trials, interrupted time series, and controlled
before-after studies, the unit of analysis might differ between our
included studies.
Dealing with missing data
We will contact investigators in order to verify key study char-
acteristics and obtain missing outcome data where possible (e.g.
when a study is identified as abstract only). For data which are
assumed to be missing at random we will use available case data as
reported by study author. If data are assumed to be ’not missing
at random’, we will impute missing data with replacement values
(e.g. using the last observation carried forward) (Higgins 2011).
We will explore any decisions to manage missing data during the
sensitivity analysis (see Sensitivity analysis).
Assessment of heterogeneity
We will assess clinical and methodological heterogeneity by con-
sideration of study design, participants and how the follow-up
clinics are conducted. Differences, for example in the socioeco-
nomic background of the participants, may influence outcome
data and substantial heterogeneity may warrant decisions not to
pool data. We will assess statistical heterogeneity using the Chi²
statistic (and related P value) or the I² statistic (with associated
percentage values). We will use the following cut-offs as a guide
to interpretation: I² at 0% to 40% is not considered important,
30% to 60% suggests moderate heterogeneity, 50% to 90% sug-
gests substantial heterogeneity, and 75% to 100% is considerable
heterogeneity (Higgins 2011). If we identify substantial clinical,
methodological or statistical heterogeneity we will explore it by
prespecified subgroup analysis.
We expect heterogeneity in randomised trials, controlled before-
after, and interrupted time series studies to derive from:
1. type of follow-up clinic used (e.g. nurse led or physician
led; face to face or remote);
2. time points of clinics;
3. time points of outcome assessment;
4. potential risk of developing PICS; and
5. socioeconomic conditions of participant.
Differences in the risk of acquiring PICS has the potential to con-
tribute to clinical heterogeneity as it has been shown that certain
factors may increase this likelihood. For example, ARDS patients
who survive the ICU may potentially be at a higher risk of de-
veloping PICS elements such as depression, anxiety and PTSD
(Davydow 2008c). Heterogeneity in this area may be assessed by
collecting patients’ baseline data in studies for presence of ARDS,
length of ICU stay, length of sedation, and APACHE II and SAPS
II scores, and making judgements based on the comparisons be-
tween these data.
Assessment of reporting biases
We will attempt to contact study authors asking them to provide
missing outcome data. Where this is not possible, and the missing
data are thought to introduce serious bias, the impact of including
such studies on the overall assessment of results will be explored
by a sensitivity analysis. If we are able to pool more than 10 trials,
we will create and examine a funnel plot to explore possible publi-
cation biases, interpreting the results with caution (Sterne 2011).
Data synthesis
Wewill undertakemeta-analysis only where this is meaningful, i.e.
if the treatments, participants, and the underlying clinical ques-
tion are similar enough for pooling to make sense. We will pay
attention to scales used to measure continuous outcomes and only
combine data if these scales appear to be equivalent. However,
while commonly-used scales such as SF-36 and EQ-5D are vali-
dated (Brazier 1993), we do not anticipate that the combined data
for the two scales, or any equivalent scales, will be suitable for pool-
ing. A common way that trialists indicate when they have skewed
data is by reporting medians and interquartile ranges. When we
encounter this, we will note that the data are skewed and consider
the implication of this.
Given the differences in the HRQoL metrics, we will use the stan-
dardised mean difference for continuous data, together with the
appropriate associated 95% confidence interval, and risk ratio for
dichotomous data, together with the appropriate associated 95%
confidence interval. We will ensure that an increase in scores for
continuous outcomes can be interpreted in the same way for each
outcome, explain the direction to the reader, and report where
the directions were reversed if this was necessary. If we need to
standardise different data sets, we will consult statistical support.
The use of the standardised mean difference will account for an-
ticipated differences in scales. We will calculate risk ratios for di-
chotomous outcomes using Mantel-Haenszel. If events are rare (1
per 1000) we will calculate Peto odds ratio (Higgins 2011) Our
choice of a fixed-effect or random-effects model for both of these
outcome measures will be based on heterogeneity (methodologi-
cal or statistical or both). We will conduct any meta-analyses and
calculate 95% confidence intervals using the RevMan calculator
(RevMan), and we will use generic inverse variance in an attempt
to address expected heterogeneity between the studies. We will
consider whether there is any additional outcome information that
was not able to be incorporated into meta-analyses, note this in
the comments, and state if it supports or contradicts the informa-
tion from the meta-analyses. We will report whether study authors
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have presented adjusted or unadjusted data with factors that have
been adjusted for. We will not combine adjusted and unadjusted
data in the same analysis. If it is not possible to meta-analyse the
data we will summarise the results in the text.
For interrupted time series designswewill conduct regression anal-
ysis or ARIMA analysis (EPOC2013b).We will report the change
in slope and the change in level. The change in slope shows the
change in trend frompre- to post-intervention, reflecting the long-
term effect of use of a follow-up service. The change in level will
show a more immediate effect of the follow-up service.
Summary of findings
We will summarise the findings of the main intervention compar-
ison for the most important outcomes (HRQoL, mortality, de-
pression and anxiety, PTSD, physical and cognitive function, time
(ability) to return to work or education, adverse effects) in a ’Sum-
mary of findings’ table to draw conclusions about the certainty
of the evidence within the text of the review. Two review authors
will independently assess the certainty of the evidence (high, mod-
erate, low, and very low) using the five GRADE considerations
(study design, consistency of effect, imprecision and indirectness;
Guyatt 2008). We will use methods and recommendations de-
scribed in Section 8.5 and Chapter 12 of the Cochrane Handbook
(Higgins 2011), and the EPOC worksheets (EPOC 2013d), and
using GRADEpro software (GRADEpro GDT 2015). We will re-
solve disagreements on certainty ratings by discussion and provide
justification for decisions to down- or up-grade the ratings using
footnotes in the table. We will make comments to aid readers’
understanding of the review where necessary. We will use plain
language statements to report these findings in the review.
Subgroup analysis and investigation of heterogeneity
We plan to carry out the following subgroup analyses, focusing
on two distinct categories: particular patient groups, and style of
service.
1. Physician-led clinic versus nurse-led clinic.
2. Face-to-face clinic versus remote clinic.
3. Participants from developing countries versus participants
from developed countries (according to WDI).
4. Intervention conducted earlier than three months post-ICU
versus three to six months.
5. Incidence of ICU delirium versus no delirium.
We will use subgroup analysis to assess whether certain follow-up
services have disproportionate benefit for different groups. Organ-
isation, style and timing of follow-up services between studies may
introduce heterogeneity (Williams 2008) and some of these differ-
ences may be explained by socioeconomic factors according to the
country of the study or inequity in access to healthcare services,
or both. For example, current UK guidelines recommend face-to-
face ICU follow-up at two to three months post-discharge (NICE
2009), which may be achievable in a developed health economy
but not in a developing country. An important socioeconomic
consideration is the influence specifically of a nation’s status as a
developing or developed economy, which can impinge upon its
citizens’ access to healthcare services. To this end, we will assess
country of study according to the World Bank’s World Develop-
ment Index (WDI) (World Bank 2016). Delirium in the ICU and
resultant cognitive dysfunction, which has been shown to be a
prevalent affliction among the ICU survivor population and can
affect quality of life (Gordon 2004), also have the potential to
contribute to this clinical heterogeneity. Such a subgroup analysis
might aid more precise targeting of resources in future studies.
We will use data collected during the Data extraction and
management stage of the review to decide the group for each study.
Subgroup analysis will be conducted if there are sufficient studies
(i.e. 10 or more (Higgins 2011)). It is anticipated that information
for these analyses will not be provided for each individual partic-
ipant in included trials and therefore subgroup analyses will be
conducted at the study level, not the participant level.We will only
conduct subgroup analysis of our primary outcome, HRQoL. We
will use Revman (RevMan) software to create subsets and test for
subgroup interactions. It is possible that, through the interactions
of multiple and competing variables between studies, the results of
these analyses will give a misleading picture of the efficacy of ICU
follow up for a particular group. We will interpret any subgroup
findings with caution.
Sensitivity analysis
We will perform sensitivity analyses defined a priori to assess the
robustness of our review methodology and explore its impact on
effect sizes. This will involve the following.
1. Restricting the analysis to published studies.
2. Restricting the analysis to studies with a low risk of
selection bias.
3. Using available case data or using imputed data (from last
observation carried forward) where studies have missing data.
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A P P E N D I C E S
Appendix 1. MEDLINE search strategy
Ovid MEDLINE Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE Daily and Ovid MEDLINE
<1946 to Present>
No. Search terms
1 Aftercare/
2 exp Counseling/
4 Long-Term Care/
5 Disease Management/
6 (diary or diaries).mp.
7 Counsel?ing.mp.
8 email.mp.
9 telephone*.mp.
10 phone*.mp.
10 ((follow up or discharge) adj2 (appointment* or consultation* or clinic* or program* or strateg* or service)).ti,ab
11 or/1-10
12 ((after or post) adj (trauma or level 3 or level three)).ti,ab
13 (survivor* adj3 (trauma or level 3 or level three)).ti,ab.
14 Survivor/
15 exp intensive care unit/ or exp intensive care/ or exp Multiple Organ Failure/ or exp Multiple Trauma/ or exp Shock/ or exp
sepsis/ or exp critical illness/ or exp Critical Care/ or (critical* adj (care or ill*)).ti,ab. or (intensive care unit* or ICU).ti,ab. or
sepsis.ti,ab. or (serious$ adj injur$).ti,ab. or multiple organ$ failure$.ti,ab. or (major adj (trauma$ or shock)).ti,ab
16 14 and 15
17 12 or 13 or 15 or 16
18 randomized controlled trial.pt.
19 controlled clinical trial.pt.
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(Continued)
20 multicenter study.pt.
21 pragmatic clinical trial.pt.
22 (random* or randomiz* or randomly).ti,ab.
23 groups.ab.
24 (trial or multicenter or multi center or multicentre or multi centre).ti
25 (intervention? or effect? or impact? or controlled or control group? or (before adj5 after) or (pre adj5 post) or ((pretest or pre
test) and (posttest or post test)) or quasiexperiment* or quasi experiment* or pseudo experiment* or pseudoexperiment* or
evaluat* or time series or time point? or repeated measur*).ti,ab
26 non-randomized controlled trials as topic/
27 Interrupted Time Series Analysis/
28 controlled before-after studies/
29 or/18-28
30 exp animals/
31 humans/
32 30 not (30 and 31)
33 review.pt.
34 meta analysis.pt.
35 news.pt.
36 comment.pt.
37 editorial.pt.
38 cochrane database of systematic reviews.jn.
39 comment on.cm.
40 (systematic review or literature review).ti.
41 or/32-40
42 29 not 41
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(Continued)
43 11 and 17 and 42
Appendix 2. Data collection form
Intervention review - randomised trials and non-randomised trials
1. General information
1. Date form completed (dd/mm/yyyy)
2. Name/ID of person extracting data
3. Report title
(title of paper/ abstract/ report that data are extracted from)
4. Report ID
(if there are multiple reports of this study)
5. Reference details
6. Report author contact details
7. Publication type
(e.g. full report, abstract, letter)
8. Study funding source
(including role of funder)
Possible conflicts of interest
(for study authors)
9. Notes:
2. Eligibility
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Study characteristics Review inclusion criteria Yes/ No / Unclear Location in text
(pg & ¶/fig/table)
10. Type of study Randomised trial
Controlled before-after study
Interrupted time series
11. Participants
12. Relevant comparison?
13. Variables of comparison
between groups
14. How were groups
formed?
15. Post-hoc study design
features
16. Types of intervention
17. Types of outcome mea-
sures
18. Decision:
19. Reason for exclusion
20. Notes:
DO NOT PROCEED IF STUDY EXCLUDED FROM REVIEW
3. Population and setting
Description Location in text
(pg & ¶/fig/table)
21. Population
description
(from which
study
participants are
drawn)
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(Continued)
22. Setting
(including lo-
cation and so-
cial context)
23. Inclusion
criteria
24. Exclusion
criteria
25. Method/s
of recruitment
of participants
26. Notes:
4. Methods
Descriptions as stated in report/paper Location in text
(pg & ¶/fig/table)
27. Aim of
study
28. Design
(e.g. par-
allel, crossover,
non-RCT)
29. Unit of al-
location
(by indi-
viduals, cluster/
groups or body
parts)
30.
Period of fol-
low-up clinic
(weeks after
discharge)
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(Continued)
31. Period
of data record-
ing (weeks af-
ter discharge)
32. Start date
33. End date
34. Dura-
tion of partici-
pation
(from recruit-
ment to last fol-
low-up)
36. Notes:
5. Participants
Provide overall data and, if available, comparative data for each intervention or comparison group.
Description as stated in report/paper Location in text
(pg & ¶/fig/table)
37. Total no. randomised (n)
(or total pop. at start of study for
NRCTs)
38. Clusters
(if applicable, no., type, no. people per
cluster)
39. Baseline imbalances
40. Withdrawals and exclusions
(if not provided below by outcome)
41. Age (Median, IQR)
42. Sex (n, %)
43. Race/ethnicity (n, %)
44. APACHE II, SAPS II
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(Continued)
45. Duration of sedation
46. Presence of ARDS
47. Reason for ICU admission
48. Co-morbidities
49. Incidence of delirium (CAM-
ICU) (%)
50. Other treatment received
(additional to study intervention)
51. Other relevant sociodemo-
graphics
52. Subgroups measured
53. Subgroups reported
54. Notes:
6. Intervention groups
Copy and paste table for each intervention and comparison group
Intervention group 1
Description as stated in report/paper Location in text
(pg & ¶/fig/table)
55. Group
name
56. No.
randomised to
group
(spec-
ify whether no.
people or clus-
ters)
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(Continued)
57.
Description
(include suffi-
cient detail for
replication, e.
g. content, dose,
components; if
it is a natural
experiment, de-
scribe the pre-
intervention)
58. Remote or
direct clinic
59. Method of
contact
60. Physician
led or nurse led
61. Du-
ration of treat-
ment period
62. Delivery
(e.g. mecha-
nism, medium,
intensity,
fidelity)
63. Providers
(e.g. no., profes-
sion, training,
ethnicity etc. if
relevant)
64. Co-inter-
ventions
65. Economic
variables
(i.
e. intervention
cost, changes in
other costs as re-
sult of interven-
tion)
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(Continued)
66. Re-
source require-
ments to repli-
cate interven-
tion
(e.g. staff num-
bers, cold
chain,
equipment)
67. Notes:
7. Control group
Description as stated in report/paper Location in text
(pg & ¶/fig/table)
68. Group
name
69. No.
randomised to
group
(spec-
ify whether no.
people or clus-
ters)
70.
Description
(include suffi-
cient detail for
replication, e.
g. content, dose,
components; if
it is a natural
experiment, de-
scribe the pre-
intervention)
71. Type of al-
ternative care
72. Method of
contact
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(Continued)
73. Du-
ration of treat-
ment period
74. Timing
(e.g. frequency,
duration of
each episode)
75. Delivery
(e.g. mecha-
nism, medium,
intensity,
fidelity)
76. Providers
(e.g. no., profes-
sion, training,
ethnicity etc. if
relevant)
77. Co-inter-
ventions
78. Economic
variables
(i.
e. intervention
cost, changes in
other costs as re-
sult of interven-
tion)
79. Re-
source require-
ments to repli-
cate interven-
tion
(e.g. staff num-
bers, cold
chain,
equipment)
80. Notes:
8. Outcomes
Copy and paste table for each outcome.
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Outcome 1
Description as stated in report/paper Location in text
(pg & ¶/fig/table)
81. Outcome
name
82. Time
points
measured
(specify
whether from
start or end of
intervention)
83. Time
points
reported
84. Outcome
definition
(with diagnos-
tic criteria
if relevant and
note whether
the outcome is
desirable or un-
desirable if this
is not obvious)
85. Person
measuring/
reporting
86. Unit of
measurement
(if relevant)
87. Scales: up-
per and lower
limits
(indicate
whether high or
low score is
good)
88. Is out-
come/tool val-
idated?
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(Continued)
89. Imputa-
tion of missing
data
(e.g. assump-
tions made for
ITT analysis)
90. Assumed
risk estimate
(e.g. baseline or
population risk
noted in Back-
ground)
91. Notes:
9. Results
Copy and paste the appropriate table for each outcome, including additional tables for each time point and subgroup as required.
For randomised or non-randomised trial - dichotomous outcome
Description as stated in report/paper Location in text
(pg & ¶/fig/table)
92.
Comparison
93. Outcome
94. Subgroup
95. Time point
(specify whether
from start or end
of intervention)
96. Results
Note whether:
post-
intervention OR
change from
baseline
And whether
Intervention Comparison
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(Continued)
Adjusted OR
Unadjusted
No. participants No. events No. participants
97. Baseline
data
Intervention Comparison
No. participants No. events No. participants
98. No. missing
participants and
reasons
99. No. par-
ticipants moved
from
other group and
reasons
100. Any other
results reported
101. Unit of
analysis
(e.g. by individ-
uals, health pro-
fessional,
practice, hospi-
tal, community)
102.
Statisticalmeth-
ods used and ap-
propriateness of
these methods
(e.g. adjustment
for correlation)
103. Reanalysis
required?
(if yes, specify
why, e.g. correla-
tion adjustment)
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(Continued)
104. Reanalysis
possible?
105. Reanal-
ysed results
106. Notes:
For randomised or non-randomised trial - continuous outcome
Description as stated in report/paper Location in text
(pg & ¶/fig/table)
105. Comparison
106. Outcome
107. Subgroup
108. Time point
(specify whether from start or end
of intervention)
109. Post-intervention or change
from baseline?
110. Results
Note whether:
post-
intervention OR
change from
baseline
and whether
Adjusted OR
Unadjusted
Intervention Comparison
Mean/median No. participants Mean/median SD (IQR) No. participants
111. Baseline
data
Intervention Comparison
Mean/median No. participants Mean/median SD (IQR) No. participants
112.No.missing participants and
reasons
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(Continued)
113. No. participants moved
from other group and reasons
114. Any other results reported
115. Unit of analysis
(e.g. by individuals, health profes-
sional, practice, hospital, commu-
nity)
116. Statistical methods used and
appropriateness of these methods
(e.g. adjustment for correlation)
117. Reanalysis required?
(if yes, specify why)
118. Reanalysis possible?
119. Reanalysed results
120. Notes:
For randomised or non-randomised trial - other outcome
Description as stated in report/paper Location in text
(pg & ¶/fig/table)
121. Compari-
son
122. Outcome
123. Subgroup
124. Time
point
(specify whether
from start or end
of intervention)
125. Type of
outcome
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(Continued)
126. Results Intervention re-
sult
SD (or other vari-
ance)
Control result SD (or other variance)
Overall results SE (or other variance)
127. No. partic-
ipant
Intervention Control
128. No. miss-
ing participants
and reasons
129. No. par-
ticipants moved
from
other group and
reasons
130. Any other
results reported
131. Unit of
analysis
(e.g. by individ-
uals, health pro-
fessional,
practice, hospi-
tal, community)
132.
Statisticalmeth-
ods used and ap-
propriateness of
these methods
133. Reanalysis
required?
(if yes, specify
why)
134. Reanalysis
possible?
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(Continued)
135. Reanal-
ysed results
136. Notes:
For controlled before-after study
Description as stated in report/paper Location in text
(pg & ¶/fig/table)
137. Compari-
son
138. Outcome
139. Subgroup
140. Timepoint
(specify whether
from start or end
of intervention)
141. Post-inter-
vention
or change from
baseline?
142. Results SD (or other variance) Control result SD (or other variance)
Overall results SE (or other variance)
143. No. partic-
ipants
Intervention Control
144. No. miss-
ing participants
and reasons
145. No. par-
ticipants moved
from
other group and
reasons
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(Continued)
146. Any other
results reported
147. Unit of
analysis
(individuals,
cluster/ groups or
body parts)
148.
Statisticalmeth-
ods used and ap-
propriateness of
these methods
149. Reanalysis
required?
(specify)
150. Reanalysis
possible?
151. Reanal-
ysed results
152. Notes:
For interrupted time series or repeated measures study
Description as stated in report/paper Location in text
(pg & ¶/fig/table)
153. Compari-
son
154. Outcome
155. Subgroup
156. Length of
time points
measured
(e.g. days,
months)
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(Continued)
Total period
measured
157. No. of par-
ticipants
measured
158.
No. of missing
participants and
reasons
159. No.
of time points
measured
160. Pre-intervention 161. Post-intervention
162. Mean
value
(with variance
measure)
163. Difference
in means (post -
pre)
164. Percent
relative change
165. Result re-
ported by au-
thors
(with variance
measure)
166. Unit of
analysis
(individuals or
cluster/ groups)
167.
Statisticalmeth-
ods used and ap-
propriateness of
these methods
168. Reanalysis
required?
(specify)
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(Continued)
169. Reanalysis
possible?
170. Individual
time point re-
sults
171. Read from
figure?
172. Reanal-
ysed results
SE Change in slope SE
173. Notes:
10. Applicability
174. Have important populations been ex-
cluded from the study?
(consider disadvantaged populations, and possible
differences in the intervention effect)
Yes/No/Unclear
175. Is the intervention likely to be aimed at
disadvantaged groups?
(e.g. lower socioeconomic groups)
Yes/No/Unclear
176. Does the study directly address the review
question?
(any issues of partial or indirect applicability)
Yes/No/Unclear
177. Notes:
11. Other information
Description as stated in report/paper Location in text
(pg & ¶/fig/table)
178.
Key conclusions
of study authors
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(Continued)
179. References
to other relevant
studies
180. Cor-
respondence re-
quired for fur-
ther study infor-
mation
(what and from
whom)
181. Further
study informa-
tion requested
(from whom,
what and when)
182. Cor-
respondence re-
ceived
(from whom,
what and when)
183. Notes:
Appendix 3. Modified ’Risk of bias’ tool
Domain Description Review authors’ judgement
Sequence generation
Allocation concealment
Blinding of participants and personnel
Blinding of outcome assessors
Incomplete outcome data
Selective reporting
Other sources of bias
Baseline outcomes
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(Continued)
Contamination
Baseline characteristics
Intervention independent? (ITS)
Appropriate analysis? (ITS)
Shape of effect prespecified? (ITS)
Effect on data collection? (ITS)
Blinding (ITS)
Incomplete outcome data (ITS)
Selective reporting (ITS)
Other sources of bias (ITS)
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